Abstract
Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1705-1708 |
| Number of pages | 4 |
| Journal | Journal of Infectious Diseases |
| Volume | 205 |
| Issue number | 11 |
| DOIs | |
| State | Published - Jun 1 2012 |
Funding
Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (grant numbers AI30036, AI37856 and AI36973) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Potential conflicts of interest. All authors: No reported conflicts.
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
